Direct Effect of Remifentanil and Glycine Contained in Ultiva® on Nociceptive Transmission in the Spinal Cord: In Vivo and Slice Patch Clamp Analyses

BACKGROUND: Ultiva® is commonly administered intravenously for analgesia during general anaesthesia and its main constituent remifentanil is an ultra-short-acting μ-opioid receptor agonist. Ultiva® is not approved for epidural or intrathecal use in clinical practice. Previous studies have reported t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sumie, Makoto, Shiokawa, Hiroaki, Yamaura, Ken, Karashima, Yuji, Hoka, Sumio, Yoshimura, Megumu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714899/
https://www.ncbi.nlm.nih.gov/pubmed/26771515
http://dx.doi.org/10.1371/journal.pone.0147339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714899/
https://www.ncbi.nlm.nih.gov/pubmed/26771515
http://dx.doi.org/10.1371/journal.pone.0147339

Ejemplares similares